https://www.dermatologytimes.com/view/experts-present-background-on-jak-inhibitor-vs-systemic-immunosuppressant-safety-study
0
0
8/16/23 at 8:16pm
Organization
Dermatologytimes.com
43 words
0
Comments
Christopher Bunick, MD, PhD, introduces the objectives and design of a study comparing the safety of Janus Kinase (JAK) inhibitors and systemic immunosuppressants in the treatment of atopic dermatitis (AD).
You are the first to view
Create an account
or login to join the discussion